194 related articles for article (PubMed ID: 18219395)
1. Bone building with bortezomib.
Roodman GD
J Clin Invest; 2008 Feb; 118(2):462-4. PubMed ID: 18219395
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Bonomini S; Crugnola M; Mancini C; Martella E; Ferrari L; Tabilio A; Rizzoli V
Blood; 2007 Jul; 110(1):334-8. PubMed ID: 17371942
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
Mukherjee S; Raje N; Schoonmaker JA; Liu JC; Hideshima T; Wein MN; Jones DC; Vallet S; Bouxsein ML; Pozzi S; Chhetri S; Seo YD; Aronson JP; Patel C; Fulciniti M; Purton LE; Glimcher LH; Lian JB; Stein G; Anderson KC; Scadden DT
J Clin Invest; 2008 Feb; 118(2):491-504. PubMed ID: 18219387
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib for previously untreated multiple myeloma.
Delforge M
Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
[TBL] [Abstract][Full Text] [Related]
5. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
Oyajobi BO; Garrett IR; Gupta A; Flores A; Esparza J; Muñoz S; Zhao M; Mundy GR
Br J Haematol; 2007 Nov; 139(3):434-8. PubMed ID: 17910634
[TBL] [Abstract][Full Text] [Related]
7. Current status of bortezomib in the treatment of multiple myeloma.
Cavo M
Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
[TBL] [Abstract][Full Text] [Related]
8. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
10. Impact of bortezomib on bone health in myeloma: a review of current evidence.
Zangari M; Terpos E; Zhan F; Tricot G
Cancer Treat Rev; 2012 Dec; 38(8):968-80. PubMed ID: 22226939
[TBL] [Abstract][Full Text] [Related]
11. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Chauhan D; Tian Z; Nicholson B; Kumar KG; Zhou B; Carrasco R; McDermott JL; Leach CA; Fulcinniti M; Kodrasov MP; Weinstock J; Kingsbury WD; Hideshima T; Shah PK; Minvielle S; Altun M; Kessler BM; Orlowski R; Richardson P; Munshi N; Anderson KC
Cancer Cell; 2012 Sep; 22(3):345-58. PubMed ID: 22975377
[TBL] [Abstract][Full Text] [Related]
12. Orthopaedics: Structural support.
Berglund J
Nature; 2011 Dec; 480(7377):S56-7. PubMed ID: 22169807
[No Abstract] [Full Text] [Related]
13. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; Vande Broek I; De Raeve H; Coulton L; Van Camp B; Croucher P; Vanderkerken K
Cancer Res; 2009 Jul; 69(13):5307-11. PubMed ID: 19531653
[TBL] [Abstract][Full Text] [Related]
14. Myeloma bone disease and proteasome inhibition therapies.
Terpos E; Sezer O; Croucher P; Dimopoulos MA
Blood; 2007 Aug; 110(4):1098-104. PubMed ID: 17494860
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological and clinical profile of Bortezomib (Velcade)].
Fujii H; Kotobuki Y; Nomura S; Harada Y
Nihon Yakurigaku Zasshi; 2007 Nov; 130(5):421-9. PubMed ID: 18000359
[No Abstract] [Full Text] [Related]
16. The effects of bortezomib on bone disease in patients with multiple myeloma.
Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
[TBL] [Abstract][Full Text] [Related]
17. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Tanaka T; Yamasaki R; Omura H; Hino N
Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
[No Abstract] [Full Text] [Related]
18. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Eda H; Aoki K; Kato S; Okawa Y; Takada K; Tanaka T; Marumo K; Ohkawa K
Eur J Haematol; 2010 Jul; 85(1):68-75. PubMed ID: 20192985
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma.
Kyle RA; Rajkumar SV
N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
[No Abstract] [Full Text] [Related]
20. The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
Lin HH; Hwang SM; Wu SJ; Hsu LF; Liao YH; Sheen YS; Chuang WH; Huang SY
PLoS One; 2014; 9(4):e94395. PubMed ID: 24722177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]